✦ LIBER ✦

P-508 Elderly patients benefit from second-line cytotoxic chemotherapy for advanced non-amall cell lung cancer

✍ Scribed by Kelly, K.; Langer, C.; Rosell, R.; Hanna, N.; Shepherd, E.; Einhorn, L.; Nguyen, B.; Paul, S.; McAndrews, P.; Bunn, P.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Assessing clinical benefit (CB) of chemo

✍ Lippe, P; Silva, R.R; Giuliodori, L; Massacesi, C; Battelli, N; Cellerino, R 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 105 KB

Second-Line Chemotherapy with a Modified

✍ Carmelo Tibaldi; Ilaria Bernardini; Antonio Chella; Francesa Russo; Enrico Vasil 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 134 KB

18 Chemotherapy or tyrosine kinase inhib

✍ Jyoti, B.; McKay, M.; Wong, H.; Alam, F.; Eswar, C.; Jain, P.; Littler, J.A.H.; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 43 KB

90P ERLOTINIB VS CHEMOTHERAPY AS SECOND

✍ Garde, J.; García, J.; Berzosa, M.; Marin, S.; Sangrador, C.; Piera, N.; Hidalgo 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 45 KB

P-7 Docetaxel as second-line chemotherap

✍ Barradas, Pedro S.; Oliveira, Ana S.; Costa, Agostino S.; Figueiredo, Ana M.; Al 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 183 KB

Dose intensity correlate with survival i

✍ Luciani, A.; Bertuzzi, C.; Ascione, G.; Di Gennaro, E.; Bozzoni, S.; Zonato, S.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 146 KB